Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of “Hold” by Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received an average rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $62.8333.

Several equities research analysts have issued reports on SUPN shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald increased their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Supernus Pharmaceuticals Stock Down 0.6%

NASDAQ:SUPN traded down $0.29 during trading hours on Friday, hitting $48.46. 1,126,232 shares of the company’s stock traded hands, compared to its average volume of 929,022. The firm has a market cap of $2.81 billion, a P/E ratio of -95.02, a P/E/G ratio of 1.04 and a beta of 0.54. The business’s fifty day simple moving average is $47.10 and its two-hundred day simple moving average is $49.49. Supernus Pharmaceuticals has a 52 week low of $32.20 and a 52 week high of $59.68.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. Handelsbanken Fonder AB raised its stake in shares of Supernus Pharmaceuticals by 8.9% during the second quarter. Handelsbanken Fonder AB now owns 20,716 shares of the specialty pharmaceutical company’s stock worth $964,000 after acquiring an additional 1,700 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 2.0% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 90,213 shares of the specialty pharmaceutical company’s stock valued at $4,196,000 after purchasing an additional 1,759 shares in the last quarter. Empowered Funds LLC purchased a new position in Supernus Pharmaceuticals in the 1st quarter worth $264,000. Bank of America Corp DE lifted its stake in Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Supernus Pharmaceuticals by 26.9% during the first quarter. California State Teachers Retirement System now owns 67,686 shares of the specialty pharmaceutical company’s stock valued at $3,499,000 after buying an additional 14,347 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.